BICO Group

BICO Group
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Founded in 2016, BICO (formerly CELLINK) is the leading Bio Convergence company in the world by combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,000 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

CELLINK publishes Annual Report 2019/2020

Wed, Mar 17, 2021 16:50 CET

CELLINK has published Annual Report 2019/2020 for the financial year which covers September 1, 2019 to December 31, 2020. The Annual Report is available on CELLINK’s website: www.cellink.com/investors. The printed version of Annual Report 2019/2020 will be available during calendar week 13. For more information, please contact:Isabelle Ljunggren, Head of Communications CELLINKPhone: +46 708-30 08 90Email: il@cellink.com This is information that CELLINK is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 16:50 CET

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Links

CELLINK publishes Annual Report 2019/2020